Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience Corporation (Nasdaq: TWST) has launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to enhance accuracy and efficiency in library construction for next-generation sequencing (NGS). This kit is particularly suitable for challenging applications, including liquid biopsy and somatic variant testing, and excels with samples of limited or degraded DNA, such as banked oncology samples. The launch emphasizes the importance of robust sample preparation technologies for generating high-quality sequencing data.
Twist Bioscience Corporation (NASDAQ: TWST) announced participation in two upcoming virtual investor conferences. CEO Emily Leproust and CFO Jim Thorburn will present at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 AM ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:50 PM ET. Both presentations will be webcast live and available for replay for 30 days. Twist Bioscience is known for its innovative synthetic DNA technology, providing products across various sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announces its support for the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. This initiative aims to advance ethical standards in engineering biology, which has significantly impacted fields like medicine and agriculture. The U.S. engineering biology sector contributed 5.1% to GDP in 2016. Twist emphasizes its commitment to biosecurity and ethical practices while encouraging collaboration among the scientific community to ensure responsible innovation.
Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q2 FY2021, ending March 31, 2021. Total orders reached $41.7 million, up from $24.6 million year-over-year. Revenue grew to $31.2 million, compared to $19.3 million in the prior year. However, net loss for the quarter increased to $37.9 million, or $0.78 per share. The cash position stood robust at $555.7 million. The company is optimistic about growth in the second half of the fiscal year, particularly in its NGS and synthetic biology segments.
Twist Bioscience (Nasdaq: TWST) has announced a collaboration with Vivlion GmbH to develop CRISPR gRNA libraries for various applications in genome engineering and drug development. This partnership leverages Twist's high-quality synthetic DNA production capabilities and Vivlion's innovative 3Cs technology for creating uniform CRISPR libraries. The collaboration aims to enhance genomic research efficiency, enabling faster gene function analysis. The joint effort is expected to significantly impact R&D in functional genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its lease for the 'Factory of the Future' near Portland, Oregon, adding approximately 100,000 square feet to its existing 110,000-square-foot facility. This expansion supports the company's planned growth in synthetic DNA, including potential verticals like DNA data storage. CEO Emily M. Leproust emphasized the need for strategic space planning for future market opportunities. The financial commitment for the expansion begins in 2022, aiming to bolster Twist’s capabilities in synthetic biology and genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a partnership with Pure Biologics to enhance the discovery of immuno-oncology antibody-based drugs. Through this collaboration, Twist Biopharma will provide Pure Biologics with access to synthetic antibody phage display libraries, optimized with advanced techniques including AI and big data analytics. The partnership aims to identify and optimize novel antibody candidates for therapeutic applications, with Pure Biologics committing to annual technology access fees and future milestone payments for successful outcomes.
Twist Bioscience (TWST) announced it will acquire rights to a GPCR library and proprietary Twist Antibody Optimization software developed with Distributed Bio. This acquisition, initiated in 2016, enhances Twist's capabilities in antibody discovery using its silicon DNA synthesis platform. The GPCR library contributes to a 'Library of Libraries' with over 10 billion antibodies, facilitating optimized therapeutics. The financial terms remain undisclosed, and the move supports Twist's growth in synthetic biology and genomics, aiming to advance drug discovery and development.
AcornMed Biotechnology has announced a partnership with Twist Bioscience to integrate Twist's next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's cancer precision medicine tests. This collaboration aims to enhance genetic analysis for better treatment strategies. Dr. Feng Lou, CTO of AcornMed, emphasized the importance of Twist's quality DNA synthesis in improving diagnostic accuracy. The partnership is expected to positively influence patient treatment and healthcare costs in China.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
